Investors

Press Releases

ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

December 9, 2019

  Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT…

Read more

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

December 6, 2019

Geneva, Switzerland and Boston, MA –December 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…

Read more

ObsEva Announces Third Quarter 2019 Financial Results

November 7, 2019

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the…

Read more

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

November 7, 2019

Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:…

Read more

ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

November 6, 2019

Geneva, Switzerland and Boston, MA –November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

November 6, 2019

Geneva, Switzerland and Boston, MA – November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…

Read more

ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

November 4, 2019

Geneva, Switzerland and Boston, MA –November 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical…

Read more

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

October 31, 2019

FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV…

Read more

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

October 11, 2019

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…

Read more

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

October 9, 2019

Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue